Therapy Areas: Inflammatory Diseases
Formation Bio acquires worldwide rights to FHND5032 from CTFH
30 January 2026 - Formation Bio, an AI-native pharma company, and Chinese pharmaceutical company Jiangsu Chia Tai Feng Hai Pharmaceutical Co Ltd (CTFH) announced on Thursday that Formation Bio has acq...
Almirall receives China approval for Seysara to treat moderate-to-severe acne
29 January 2026 - Spanish pharmaceutical company Almirall, S.A. (BME:ALM) announced on Thursday that China's National Medical Products Administration (NMPA) has approved Seysara (sarecycline hydr...
OSE Immunotherapeutics prioritises pouchitis and hidradenitis suppurativa for lusvertikimab development
29 January 2026 - French biotechnology company OSE Immunotherapeutics SA (Euronext Paris:OSE) said on Thursday that it has selected chronic pouchitis and hidradenitis suppurativa as new key clinical i...
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
29 January 2026 - WuXi Biologics (HK:2269), a China-based global Contract Research, Development, and Manufacturing Organisation (CRDMO), announced on Wednesday that it has formed a collaboration with ...
Physiomics secures new modelling contract with Numab Therapeutics
28 January 2026 - Mathematical modelling, data science and biostatistics company Physiomics plc (AIM: PYC) announced on Wednesday that it has been awarded a new contract by long-standing client Numab ...
Simcere Pharmaceutical enter licence and collaboration agreement with Boehringer Ingelheim
28 January 2026 - China-based Simcere Pharmaceutical Group Ltd (HKEX:2096), announced on Tuesday that it has signed a licence and collaboration agreement with Germany-based pharmaceutical company Boeh...